Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neurana Pharmaceuticals Inc.

Latest From Neurana Pharmaceuticals Inc.

Venture Funding Deals: Two Companies With China Ties Raise $260m Each

Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.

Deals Financing

Finance Watch: Lots Of Money, Big And Small, Flowing Into Drug Development

Big venture capital bets continue in biopharma, including Foresite's new $668m fund and Merck's $125m investment in Moderna, but small VC rounds could be making a comeback. In public company financings, Aslan and Evelo launched in the US, while Ascletis is testing Hong Kong’s IPO market.

Financing StartUps and SMEs

Pain Drug Development Becomes Personalized

Advances in pain neurobiology point to the promise of more specific drugs with fewer side effects, yet the field continues to show few successes. Nevertheless, fast-advancing knowledge, a huge market, and better clinical study de-risking strategies should eventually overcome investor shyness about backing emerging personalized pain drug developers.

BioPharmaceutical United States

Start-Up Previews, January 2013

This Month's Profile Group: Personalized Pain Drug Development features profiles of Adynxx, Afferent Pharmaceuticals, and Katama Pharmaceuticals. Plus these Start-Ups Across Health Care: Cognoptix, Endo Tools Therapeutics, ExThera Medical, and Kite Pharma.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Katama Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neurana Pharmaceuticals Inc.
  • Senior Management
  • David Hale, Chmn., Pres. & CEO
    Kathy Scott, CFO
    Judy Caron, PhD, COO & Head, Clinical Dev.
    Randall Kaye, MD, CMO
  • Contact Info
  • Neurana Pharmaceuticals Inc.
    3525 Del Mar Heights Rd.
    Ste. 609
    San Diego, CA 92130